NRx Pharmaceuticals, Inc. (NRXP): Price and Financial Metrics

NRx Pharmaceuticals, Inc. (NRXP): $3.04

0.02 (+0.66%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add NRXP to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#169 of 362

in industry

NRXP Price/Volume Stats

Current price $3.04 52-week high $12.00
Prev. close $3.02 52-week low $2.21
Day low $3.00 Volume 232,040
Day high $3.25 Avg. volume 180,633
50-day MA $4.88 Dividend yield N/A
200-day MA $3.80 Market Cap 29.09M

NRXP Stock Price Chart Interactive Chart >


NRx Pharmaceuticals, Inc. (NRXP) Company Bio


NRX Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company specializes in researching investigational medicines and is engaged in the development of medicines and vaccines for Covid-19, other respiratory conditions, suicidal depression, and PTSD.


NRXP Latest News Stream


Event/Time News Detail
Loading, please wait...

NRXP Latest Social Stream


Loading social stream, please wait...

View Full NRXP Social Stream

Latest NRXP News From Around the Web

Below are the latest news stories about NRX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate NRXP as an investment opportunity.

NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company today announced that Janet Rehnquist has been elected to the Company's Board of Directors where she will chair the compliance and the nominating committees.

Yahoo | December 27, 2023

NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Depression

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it has signed a License Data and Technical Information Agreement with Columbia University for rights to data from a randomized, active-controlled trial of 80 patients hospitalized for Acute Suicidality in Depression. This represents NRx's second well-controlled trial demonstrating the efficacy of IV Ketamine in this indication.

Yahoo | December 19, 2023

NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company today announced that its Investigational New Drug Application (IND) for the use of NRX-101, the company's patented combination of D-cycloserine and lurasidone, for the treatment of complicated Urinary Tract infections (cUTI), received clearance from the US FDA.

Yahoo | December 18, 2023

NRx Pharmaceuticals Provides Notice of Annual Meeting of Shareholders

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, announced their 2023 Annual Meeting of Stockholders (the "Annual Meeting") to be held on December 19, 2023, at 11:00 a.m., Eastern Time, in virtual-only format at https://www.cstproxy.com/nrxpharma/am2023.

Yahoo | December 13, 2023

NRx Pharmaceuticals to Participate in LifeSci Corporate Access Event

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced the Company will be participating in-person at the LifeSci Partners Corporate Access Event for three days from January 8th through the 10th in San Francisco.

Yahoo | December 11, 2023

Read More 'NRXP' Stories Here

NRXP Price Returns

1-mo -37.32%
3-mo -28.44%
6-mo 1.37%
1-year -49.34%
3-year -98.97%
5-year N/A
YTD -33.91%
2023 -58.56%
2022 -76.78%
2021 -80.41%
2020 130.19%
2019 3.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!